Home News & Events Press releases Press releases Page tools Share Share Share on FacebookShare on XShare on LinkedinShare on Bluesky Print Search Email Accessibility Category AcquisitionsAwardsCorporate earningsESGInvestor conferencesLeadershipTechnologyWhitepaper Year 2026202520242023202220212020201920182017 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media What’s happening in ICON ICON Plc At ICON, Study Start Up teams play a critical role in accelerating timelines, from site identification and feasibility through to contracting and activation. In this blog, James Pereira shares how leadership in start up... 19 Mar 2 View post View webpage ICON Plc Attending the World Vaccine Congress? Join ICON’s Dinah Knotts-Keeterle as she discusses ‘AI and the future of vaccine studies from reaction to readiness’. Learn more on 1 April at 12:10 pm. https://ow.ly/9Uk050Yr8VL 19 Mar View post View webpage ICON Plc With ADC innovation accelerating across Asia, Europe and the US, regulatory synchronisation has never been more important. ICON’s latest article in BioSpectrum Asia explores why proactive scientific advice, dose optimis... 19 Mar View post View webpage ICON Plc From early scientific advice to accelerated review programmes, strategic regulatory planning is essential for efficient ADC development. ICON’s latest feature explores how global agencies are approaching these hybrid mo... 19 Mar 2 View post View webpage ICON Plc At #DIAEurope2026 on 25 March from 03:00 pm to 04:10 pm, Dr. Anne Behringer will present virtually on ‘Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality’. Discover more. https://ow.ly/ZXk7... 18 Mar View post View webpage ICON Plc On 30 March - 2 April at World Vaccine Congress, meet ICON experts at booth #222 to learn about our 30+ years of experience supporting vaccine development for biotech, pharma, government, and NGOs. https://ow.ly/GzT350Yr... 18 Mar 4 View post View webpage ICON Plc Attending the GLP-1-Based Therapeutics Summit in Boston? On 15 April at 12:00 pm, ICON’s Alan Baldridge will be presenting, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He’... 18 Mar View post View webpage ICON Plc Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil... 18 Mar View post View webpage ICON Plc Clinical trials are powered by people. Behind every study is a cross functional team working across countries, time zones and specialist areas to deliver safe, high quality research. From study start up and site activa... 17 Mar 1 View post View webpage ICON Plc Thank you to everyone who joined our Rare Disease Day webinar. From gene targeted therapies to accelerated approvals, the inspiring discussion highlighted how patient leadership continues to shape ultra rare disease drug... 17 Mar View post View webpage ICON Plc Missed our Rare Disease Day webinar or want to rewatch the discussion? Hear real world examples of how patient led organisations are breaking barriers in ultra rare disease drug development. Watch the recording today: ht... 17 Mar 1 View post View webpage ICON Plc Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a... 17 Mar 1 View post View webpage
